Nonhomologous end joining key factor XLF enhances both 5-florouracil and oxaliplatin resistance in colorectal cancer
Sign Up to like & getrecommendations! Published in 2019 at "OncoTargets and therapy"
DOI: 10.2147/ott.s192923
Abstract: Background Colorectal cancer (CRC) is the third commonly diagnosed cancer with a high risk of death. After curative surgery, 40% of patients will have metastases or develop recurrence. Therefore, chemotherapy is significantly responsible as the… read more here.
Keywords: factor xlf; colorectal cancer; key factor; xlf ... See more keywords